Next Generation Antibody Drug Market Report 2026

The next generation antibody drug market size has grown rapidly in recent years. It will grow from $16.4 billion in 2025 to $18.93 billion in 2026 at a compound annual growth rate (CAGR) of 15.4%. The growth in the historic period can be attributed to success of monoclonal antibody therapies, rising cancer prevalence, advancements in antibody engineering, increased biologics r&d investment, regulatory approvals of antibody drugs.

The next generation antibody drug market size is expected to see rapid growth in the next few years. It will grow to $33.53 billion in 2030 at a compound annual growth rate (CAGR) of 15.4%. The growth in the forecast period can be attributed to growth in precision medicine adoption, increasing demand for targeted biologics, advancements in conjugation technologies, expansion of autoimmune disease treatments, rising oncology drug pipelines. Major trends in the forecast period include rapid development of bispecific antibodies, increasing adoption of antibody-drug conjugates, growing focus on precision targeted therapies, expansion of antibody applications beyond oncology, rising clinical trials for advanced antibody platforms.

The growing emphasis on personalized medicine is expected to drive the expansion of the next-generation antibody-drug market in the coming years. Personalized medicine is a medical approach that customizes treatment and healthcare strategies for individual patients based on their genetic, environmental, and lifestyle factors, enabling more effective and targeted therapies. Its adoption is increasing due to advancements in genomic sequencing, which allow for more precise diagnoses and tailored treatment strategies. Next-generation antibody drugs support personalized medicine by enabling the development of targeted therapies adapted to patients’ specific genetic profiles and disease characteristics, enhancing efficacy while reducing adverse effects. For example, in February 2024, the Personalized Medicine Coalition, a U.S.-based organization promoting personalized medicine, reported that the U.S. Food and Drug Administration (FDA) approved 16 new personalized treatments for rare disease patients in 2023, up from 6 in 2022. Consequently, the rising focus on personalized medicine is fueling growth in the next-generation antibody-drug market.

Leading companies in the next-generation antibody-drug market are concentrating on developing innovative solutions, such as antibody-drug conjugates, to improve targeted cancer therapies, enhance therapeutic efficacy, and reduce systemic toxicity. An antibody-drug conjugate (ADC) is a targeted cancer treatment that links a monoclonal antibody to a cytotoxic drug via a linker, allowing the drug to be delivered selectively to tumor cells while minimizing harm to healthy tissue. For example, in January 2024, BioNTech SE, a Germany-based biotechnology company, partnered with Duality Biologics (Suzhou) Co. Ltd., a China-based pharmaceutical company, and received Fast Track designation from the U.S. Food and Drug Administration (FDA) for their next-generation ADC candidate, BNT325/DB-1305, designed to treat platinum-resistant ovarian cancer. The drug leverages DualityBio's DITAC (Duality Immune Toxin Antibody Conjugates) platform, which combines a highly potent cytotoxic payload with a monoclonal antibody, enabling precise delivery of treatment directly to cancer cells. BNT325/DB-1305’s ability to accurately target cancer cells while minimizing damage to healthy tissue is a key advantage in improving treatment efficacy and reducing side effects.

In March 2024, Johnson & Johnson, a U.S.-based pharmaceutical company, acquired Ambrx Biopharma for an undisclosed amount. Through this acquisition, Johnson & Johnson aims to expand its oncology portfolio by developing innovative, targeted antibody-drug conjugates that enhance treatment outcomes and minimize side effects for patients with hard-to-treat cancers. Ambrx Biopharma Inc. is a U.S.-based company focused on advancing the development of next-generation antibody-drug conjugates (ADCs).

Major companies operating in the next generation antibody drug market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals Inc., Biogen Inc., Kyowa Hakko Kirin Co. Ltd., Samsung Biologics Co. Ltd., WuXi Biologics Inc., Akeso Inc., Xencor Inc., ImmunoGen Inc., Philogen S.p.A., Telix Pharmaceuticals Limited, Actinium Pharmaceuticals Inc.

North America was the largest region in the next generation antibody drug market in 2025. The regions covered in the next generation antibody drug market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the next generation antibody drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the next generation antibody drug market by increasing costs of imported biologic raw materials, manufacturing equipment, and cold-chain logistics. These impacts are most evident in adc and bispecific antibody segments across North America, Europe, and Asia-Pacific. Higher tariffs have increased drug development and commercialization costs. Positively, tariffs have encouraged local biologics manufacturing and strengthened regional biopharma supply chains.

The next generation antibody drug market research report is one of a series of new reports that provides next generation antibody drug market statistics, including next generation antibody drug industry global market size, regional shares, competitors with a next generation antibody drug market share, detailed next generation antibody drug market segments, market trends and opportunities, and any further data you may need to thrive in the next generation antibody drug industry. This next generation antibody drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Next-generation antibody drugs are advanced therapeutic antibodies designed to target specific antigens with greater precision and efficacy, often utilizing innovative technologies such as bispecific antibodies or antibody-drug conjugates. These drugs aim to enhance treatment outcomes by improving targeting and reducing side effects.

The main product types of next-generation antibody drugs include monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and others. Monoclonal antibodies are identical copies of a single antibody produced by cloning a unique immune cell and are used to treat conditions such as cancer and autoimmune disorders. Their mechanisms of action include checkpoint inhibition, immune modulation, receptor blocking, targeted cytotoxic activity, and neutralization. These drugs can be delivered intravenously (IV), subcutaneously, intramuscularly, orally, or via transdermal systems. Applications span oncology, autoimmune diseases, infectious diseases, and more, and they are used by hospitals, research institutes, specialty clinics, and other healthcare providers.

The next generation antibody drug market consists of sales of engineered monoclonal antibodies, antibody-drug conjugates (ADCs), bispecific antibodies, and related biologic therapies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.